ALXO

ALX Oncology Holdings Inc. NASDAQ

Healthcare ·Biotechnology ·US · alxoncology.com

$1.88

After hrs $1.93 -0.26%

Mkt Cap $101.9M

52w Low $0.40 65.4% of range 52w High $2.66

50d MA $1.97 200d MA $1.51

P/E (TTM) -0.9x

EV/EBITDA -0.5x

P/B 3.5x

Debt/Equity 0.2x

ROE -391.4%

P/FCF -0.7x

RSI (14) —

ATR (14) —

Beta 0.50

50d MA $1.97

200d MA $1.51

Avg Volume 986.6K

About

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor in…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 27, 2026	AMC	-0.38	-0.42	-10.5%	2.11	-4.3%	+0.5%	-1.9%	+3.8%	+0.9%	+4.7%	—
Nov 7, 2025	AMC	-0.37	-0.41	-10.8%	1.38	-8.0%	-8.0%	-5.1%	-7.2%	-11.6%	+0.0%	—
Aug 12, 2025	AMC	-0.46	-0.49	-6.5%	0.62	+0.8%	+7.4%	+6.5%	+4.7%	+57.8%	+44.6%	—
May 8, 2025	AMC	-0.47	-0.58	-23.4%	0.46	+3.3%	-8.2%	-5.4%	+4.5%	-0.2%	-5.3%	—
Mar 6, 2025	AMC	-0.72	-0.55	+23.6%	1.31	-4.6%	-19.1%	-31.8%	-25.7%	-26.8%	-36.5%	—
Nov 7, 2024	AMC	-0.78	-0.58	+25.6%	1.51	+2.6%	-4.0%	-2.0%	-11.3%	-11.3%	-11.9%	—
Aug 8, 2024	AMC	-0.77	-0.76	+1.3%	2.63	+4.2%	-0.8%	-4.2%	+0.4%	-1.9%	+0.8%	—
May 9, 2024	AMC	-0.87	-0.71	+18.4%	16.95	+3.2%	-4.4%	-7.9%	-10.5%	-11.4%	-13.5%	—
Mar 7, 2024	AMC	-0.84	-0.93	-10.7%	16.24	-13.1%	-6.3%	-17.1%	-23.8%	-28.6%	-31.3%	—
Nov 13, 2023	AMC	-0.86	-1.24	-44.2%	8.43	-8.9%	+4.7%	+4.0%	+5.9%	+12.7%	+16.3%	—
Aug 10, 2023	AMC	-0.85	-0.84	+1.2%	5.04	-2.0%	+0.4%	-2.8%	-3.6%	-9.7%	-9.5%	—
May 11, 2023	AMC	-0.84	-0.58	+31.0%	6.27	+3.5%	+4.1%	+3.0%	-3.7%	+0.6%	-4.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.13	$2.18	+2.3%	-4.2%	+0.9%	-5.2%	-7.0%	-2.3%
Feb 5	Piper Sandler	Maintains	Overweight → Overweight	—	$2.01	$2.10	+4.5%	+2.5%	+2.0%	+16.4%	+26.9%	+23.4%
May 21	UBS	Maintains	Buy → Buy	—	$0.43	$0.43	+0.0%	-4.6%	+11.7%	+8.1%	+4.5%	+4.5%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.46	$0.48	+3.3%	-8.2%	-5.4%	+4.5%	-0.2%	-5.3%
Mar 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.31	$1.25	-4.6%	-19.1%	-31.8%	-25.7%	-26.8%	-36.5%
Mar 7	Stifel	Maintains	Hold → Hold	—	$1.31	$1.25	-4.6%	-19.1%	-31.8%	-25.7%	-26.8%	-36.5%
Mar 6	Jefferies	Upgrade	Hold → Buy	—	$1.04	$1.07	+2.9%	+26.0%	+1.9%	-14.1%	-6.4%	-7.8%
Mar 6	Piper Sandler	Maintains	Overweight → Overweight	—	$1.04	$1.07	+2.9%	+26.0%	+1.9%	-14.1%	-6.4%	-7.8%
Jan 27	UBS	Maintains	Buy → Buy	—	$1.52	$1.45	-4.6%	+2.6%	+0.7%	-3.9%	-13.8%	-3.9%
Jan 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.63	$1.55	-4.9%	-6.7%	-4.3%	-6.1%	-10.4%	-19.6%
Jan 24	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.63	$1.55	-4.9%	-6.7%	-4.3%	-6.1%	-10.4%	-19.6%
Dec 19	Jefferies	Downgrade	Buy → Hold	—	$1.84	$1.78	-3.3%	-19.6%	-12.0%	+1.6%	-0.5%	-8.2%
Dec 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.79	$1.82	+1.7%	+2.8%	-17.3%	-9.5%	+4.5%	+2.2%
Dec 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.79	$1.82	+1.7%	+2.8%	-17.3%	-9.5%	+4.5%	+2.2%
Aug 16	UBS	Maintains	Buy → Buy	—	$2.65	$2.62	-1.1%	-4.2%	-3.0%	-5.3%	-5.7%	-12.1%
Aug 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.52	$2.46	-2.4%	+4.8%	+2.4%	+5.2%	+0.8%	+2.0%
Aug 9	Stifel	Maintains	Hold → Hold	—	$2.63	$2.74	+4.2%	-0.8%	-4.2%	+0.4%	-1.9%	+0.8%
Aug 1	Stifel	Maintains	Hold → Hold	—	$4.80	$3.20	-33.3%	-41.7%	-40.4%	-43.1%	-42.7%	-46.5%
Aug 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.80	$3.20	-33.3%	-41.7%	-40.4%	-43.1%	-42.7%	-46.5%
Jun 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.01	$8.86	-1.7%	-3.8%	-5.0%	-5.3%	-6.3%	-10.7%
Apr 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.34	$12.02	-2.6%	-2.4%	+8.4%	+5.6%	+4.5%	+17.4%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.21	$15.58	+2.4%	-11.5%	-18.7%	-23.7%	-26.7%	-25.7%
Mar 8	Stifel	Downgrade	Buy → Hold	—	$16.24	$14.12	-13.1%	-6.3%	-17.1%	-23.8%	-28.6%	-31.3%
Mar 8	Piper Sandler	Maintains	Overweight → Overweight	—	$16.24	$14.12	-13.1%	-6.3%	-17.1%	-23.8%	-28.6%	-31.3%
Dec 8	Jefferies	Upgrade	Hold → Buy	—	$9.25	$10.22	+10.5%	+32.5%	+35.1%	+38.5%	+43.8%	+42.6%
Nov 14	Stifel	Maintains	Buy → Buy	—	$8.43	$7.68	-8.9%	+4.7%	+4.0%	+5.9%	+12.7%	+16.3%
Oct 11	Piper Sandler	Maintains	Overweight → Overweight	—	$9.52	$9.43	-0.9%	-4.5%	-0.7%	-4.1%	-2.6%	-10.7%
Oct 4	UBS	Maintains	Buy → Buy	—	$7.51	$7.12	-5.2%	-15.0%	-12.7%	+11.2%	+9.1%	+26.8%
Oct 4	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$7.51	$7.12	-5.2%	-15.0%	-12.7%	+11.2%	+9.1%	+26.8%
Oct 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.81	$8.09	+68.2%	+56.1%	+32.6%	+36.3%	+73.6%	+70.3%
Sep 12	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.96	$4.89	-1.4%	+1.8%	+3.8%	+1.0%	+4.4%	+4.0%
Aug 14	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$5.06	$5.02	-0.8%	-3.2%	-4.0%	-10.1%	-9.9%	-6.9%
Aug 11	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$5.04	$4.94	-2.0%	+0.4%	-2.8%	-3.6%	-9.7%	-9.5%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.04	$4.94	-2.0%	+0.4%	-2.8%	-3.6%	-9.7%	-9.5%
Aug 11	Piper Sandler	Maintains	Overweight → Overweight	—	$5.04	$4.94	-2.0%	+0.4%	-2.8%	-3.6%	-9.7%	-9.5%
Jul 24	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.73	$6.45	-4.2%	-8.5%	-12.9%	-12.9%	-15.3%	-11.7%
May 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.27	$6.49	+3.5%	+4.1%	+3.0%	-3.7%	+0.6%	-4.1%
Mar 15	UBS	Maintains	Buy → Buy	—	$5.25	$5.21	-0.8%	-1.1%	-4.8%	-9.1%	-12.2%	-8.4%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.87	$5.79	-1.4%	-8.2%	-4.1%	-10.6%	-11.6%	-14.8%
Mar 10	Credit Suisse	Maintains	Outperform → Outperform	—	$5.87	$5.79	-1.4%	-8.2%	-4.1%	-10.6%	-11.6%	-14.8%
Nov 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.50	$12.63	+1.0%	-0.6%	+0.9%	+2.3%	-1.0%	-7.2%
Aug 9	Credit Suisse	Maintains	Outperform → Outperform	—	$11.76	$11.39	-3.1%	+0.1%	+8.8%	+10.4%	+23.5%	+28.7%
Jun 6	Stifel	Maintains	Buy → Buy	—	$7.60	$7.72	+1.6%	-5.9%	+2.0%	+5.0%	+2.4%	-10.7%
May 19	Piper Sandler	Maintains	Overweight → Overweight	—	$8.64	$8.66	+0.2%	+1.4%	+1.3%	-2.1%	-10.3%	-8.6%
Mar 1	Stifel	Maintains	Buy → Buy	—	$18.12	$17.52	-3.3%	+0.1%	+4.1%	-3.9%	-8.2%	-5.4%
Dec 22	Jefferies	Downgrade	Buy → Hold	—	$22.91	$21.62	-5.6%	-2.7%	+1.5%	-2.4%	-2.8%	-4.3%
Sep 30	Stifel	Maintains	Buy → Buy	—	$73.36	$75.03	+2.3%	+0.7%	+1.4%	-3.1%	+0.7%	-6.5%
Apr 6	UBS	Maintains	Buy → Buy	—	$75.23	$76.75	+2.0%	-0.8%	-8.0%	-4.1%	-15.2%	-23.0%
Feb 11	Credit Suisse	Maintains	Outperform → Outperform	—	$80.42	$83.34	+3.6%	+0.6%	+1.7%	+1.4%	+5.8%	+6.9%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$82.18	$85.75	+4.3%	-2.1%	-1.5%	-0.5%	-0.8%	+3.5%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

Leadership transitions create uncertainty around strategic direction and operational continuity, potentially triggering stock volatility until investors assess the successor's qualifications and vision.

Apr 13

8-K

ALX Oncology Holdings Inc. -- 8-K Filing

ALX Oncology reported positive Phase 1b/2 biomarker data supporting its evorpacept and zanidatamab combination for HER2-positive breast cancer, advancing clinical development of its immunotherapy pipeline.

Feb 27

Data updated apr 24, 2026 5:37pm · Source: massive.com